KES
Search
- Page Path
- HOME > Search
Review Article
- Diabetes, obesity and metabolism
- Glucagon: Physiological and Pharmacological Functions and Pathophysiological Significance in Type 2 Diabetes
- Tadahiro Kitamura
- Endocrinol Metab. 2024;39(1):33-39. Published online February 22, 2024
- DOI: https://doi.org/10.3803/EnM.2024.1911
- 32,279 View
- 575 Download
- 6 Web of Science
- 6 Crossref
-
Abstract
PDF
PubReader 
ePub - Glucagon has many functions, including the promotion of hepatic glucose production, fatty acid oxidation, thermogenesis, energy consumption, lipolysis, and myocardial contraction, as well as the suppression of lipogenesis, appetite, and gastrointestinal motility. However, it remains unclear which of these functions are physiological and which are pharmacological. Research on glucagon has lagged behind research on insulin because cross-reactivity with glucagon-related peptides in plasma has hindered the development of an accurate measurement system for glucagon. We recently developed a new glucagon sandwich enzyme-linked immunosorbent assay (ELISA) that is more specific and more sensitive to glucagon than the currently used measurement systems. The new sandwich ELISA is expected to contribute to personalized medicine for diabetes through its use in clinical examinations, the diagnosis of the pathophysiological condition of individual diabetes patients, and the choice of a treatment strategy. Efforts are continuing to develop glucagon/glucagon-like peptide-1 receptor dual agonists to improve obesity and fatty liver by enhancing glucagon’s appetite-suppressing and lipolysis- and thermogenesis-promoting effects. Thus, glucagon is expected to be applied to new diagnostic and therapeutic strategies based on a more accurate understanding of its functions.
-
Citations
Citations to this article as recorded by
- Mitochondrial-derived peptides (Humanin, MOTS-c, and SHLP2) protect pancreatic islet cells and delay the onset and progression of type 2 diabetes mellitus in mice
Tiyesh Paul, Oly Banerjee, Sangeeta Das, Bithin Kumar Maji, Srikanta Goswami, Sandip Mukherjee
PharmaNutrition.2026; 35: 100480. CrossRef - Sodium-glucose cotransporter-specific substrate αMG stimulates endogenous glucagon secretion and ameliorates obesity-associated metabolic disorders in mice
Takayoshi Suga, Yoko Tabei, Osamu Kikuchi, Daisuke Kohno, Yuichi Ikeuchi, Masaki Kobayashi, Yuko Nakagawa, Hiroki Tojima, Yuichi Yamazaki, Ken Sato, Satoru Kakizaki, Takashi Nishimura, Yoshio Fujitani, Takumi Takizawa, Toshio Uraoka, Tadahiro Kitamura
Molecular Metabolism.2026; 105: 102324. CrossRef - Association between sleep disorders and alterations in glucose metabolism, insulin, and glucagon in patients with type 2 diabetes
Zhixue Song, Huashan Zhao, Xiaoxue Yu, Xinguang Sun
Medicine.2026; 105(7): e47409. CrossRef - Antidiabetic Potential of Brewed Arabica Coffee: Modulation of GLUT4, Insulin, and Glucagon in STZ‐Induced Rats
Yusni Yusni, Hanifah Yusuf, Said Usman, Iflan Nauval, Hasanuddin Hasanuddin, Fahmi Ichwansyah, Nurul Mahmudati, Eric Gumpricht
Journal of Nutrition and Metabolism.2026;[Epub] CrossRef - The Insulin–Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles
Giovanni Tarantino, Vincenzo Citro, Ciro Imbimbo, Felice Crocetto
International Journal of Molecular Sciences.2026; 27(9): 3919. CrossRef - Coordination Chemistry of Diabetes‐Associated Islet Peptide Hormones
Yonghwan Pi, Hyunwoo Jung, Jiyeon Han
European Journal of Inorganic Chemistry.2025;[Epub] CrossRef
- Mitochondrial-derived peptides (Humanin, MOTS-c, and SHLP2) protect pancreatic islet cells and delay the onset and progression of type 2 diabetes mellitus in mice
First
Prev
